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ABSTRACT 
Cytochrome P450 2D6 (CYP2D6) is responsible for the metabolic activation of 
primaquine, an antimalarial drug. CYP2D6 is genetically polymorphic, and these 
polymorphisms are associated with interindividual variations observed in the 
therapeutic efficacy of primaquine. To further understand this association, we performed 
in vitro enzymatic analyses of the wild-type CYP2D6.1 and 49 CYP2D6 allelic 
variants, which were expressed in 293FT cells, using primaquine as a substrate. The 
concentrations of CYP2D6 variant holoenzymes were measured by using carbon 
monoxide (CO)-reduced difference spectroscopy, and the wild type and 27 variants 
showed a peak at 450 nm. The kinetic parameters Km, Vmax, and intrinsic clearance 
(Vmax/Km) of primaquine 5-hydroxylation were characterized. The kinetic parameters of 
the wild type and 16 variants were measured, but the values for the remaining 33 
variants could not be determined because of low metabolite concentrations. Among the 
variants, six (i.e., CYP2D6.17, .18, .35, .39, .53, and .70) showed significantly reduced 
intrinsic clearance compared with that of CYP2D6.1. Three-dimensional structural 
modeling analysis was performed to elucidate the mechanism of changes in the kinetics 
of CYP2D6 variants. Our findings provide insights into the allele-specific activity of 
CYP2D6 for primaquine, which could be clinically useful for malaria treatment and 
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eradication efforts. 
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1. Introduction 
Cytochrome P450 (CYP) 2D6 is involved in the metabolism of approximately 
25% of clinically used drugs, including antidepressants, β-blockers, anticancer drugs, 
opioid analgesics, and antimalarial drugs [1]. CYP2D6 polymorphisms have been 
extensively investigated in terms of their effects on enzymatic activity. Differences in 
CYP2D6 activity are derived from over 100 variants, from null alleles to gene 
amplifications (The Pharmacogene Variation Consortium; 
https://www.pharmvar.org/gene/CYP2D6) [2]. Based on their activity, CYP2D6 variants 
can be classified as belonging to one of the following phenotypes: ultrarapid 
metabolizer (UM), extensive metabolizer (EM), intermediate metabolizer (IM), and 
poor metabolizer (PM). Interindividual variations in enzyme activity cause not only 
severe adverse effects but also failures in drug responses. 
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Primaquine is the only approved antimalarial drug for the treatment of relapsing 
malaria strains (Plasmodium vivax and Plasmodium ovale). The distribution of P. vivax 
is widespread, leading to health and economic burdens, particularly in South America, 
Western Pacific regions, and Southeast Asia [3]. Primaquine is a prodrug, and CYP2D6 
and monoamine oxidase A (MAO-A) are mainly responsible for its metabolism [4–7]. 
MAO-A is involved in the production of primaquine aldehyde, with its subsequent 
conversion to carboxyprimaquine, catalyzed by aldehyde oxidase (Fig. 1). This pathway 
leads to the inactivation of primaquine. In contrast, CYP2D6 generates phenolic 
metabolites of primaquine, which are associated with redox activity [8,9]. A previous 
study using a malaria mouse model has shown that primaquine exposure was higher in 
CYP2D knockout mice than in wild-type mice, whereas phenolic metabolite levels, 
particularly those of 5-hydroxyprimaquine, remarkably decreased [10]. Moreover, 
CYP2D-deficient mice treated with primaquine became systemically infected with 
malaria, but CYP2D6 knock-in mice recovered, suggesting that CYP2D6-mediated 
metabolic activation is required for primaquine activity [9]. 5-Hydroxyprimaquine is an 
unstable metabolite and is capable of redox cycling to its corresponding quinone imine 
[8]. Because this redox cycling produces hydrogen peroxide and leads to oxidative 
stress, it is believed to be responsible for primaquine efficacy [11,12]. 
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Recent studies have suggested that impaired CYP2D6 function, caused by allelic 
polymorphisms, leads to the therapeutic failure of primaquine as a radical cure for P. 
vivax malaria [13,14]. Patients who experienced multiple malaria relapses were shown 
to be heterozygous for CYP2D6*5 and *6, CYP2D6*4 and *41, or CYP2D6*5 and *41. 
Furthermore, the activity score (AS) model developed by Gaedigk et al. allows the 
prediction of the CYP2D6 phenotype as IM (AS 0.5) or PM (AS 0) [15]. Phenotypes 
with AS ≤ 1.0 are considered to be poor primaquine metabolizers [16]. The AS of 
CYP2D6 is determined using its metabolic activity for dextromethorphan as a common 
CYP2D6 substrate [15]. However, the metabolic rates were observed to vary 
considerably with different substrates [17]. Thus, it is necessary to characterize 
CYP2D6 variant functions using primaquine to specifically investigate the association 
between CYP2D6 variant alleles and primaquine treatment failure. 
Several studies have functionally analyzed CYP2D6 variants by using 
heterologous expression systems to assess the effects of variant alleles [18]. We have 
previously determined the in vitro functions of 50 CYP2D6 variants expressed in COS-
7 cells using N-desmethyltamoxifen, bufuralol, and dextromethorphan as substrates 
[17]. The results suggested that there were functional differences among CYP2D6 
substrates. The objective of the present study was to conduct in vitro assays on 50 
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CYP2D6 variants to determine their primaquine 5-hydroxylation activities. 5-
Hydroxyprimaquine is unstable and rapidly reacts with water to form the stable 5,6-
orthoquinone. Thus, 5,6-orthoquinone was used as a surrogate marker for the presence 
of 5-hydroxyprimaquine [10]. We also performed a three-dimensional structural 
modeling analysis to elucidate the underlying mechanism of the observed changes in the 
kinetics of CYP2D6 variants. Our findings provide valuable information for the 
development of a more efficient primaquine therapy. 
 
2. Materials and methods 
2.1. Chemicals 
Primaquine bisphosphate was purchased from Sigma–Aldrich (St. Louis, MO, 
USA). Mefloquine hydrochloride was purchased from Tokyo Chemical Industry 
(Tokyo, Japan). Oxidized β-nicotinamide adenine dinucleotide phosphate (NADP+), 
glucose-6-phosphate (G-6-P), and glucose-6-phosphate dehydrogenase (G-6-PDH) were 
purchased from Oriental Yeast (Tokyo, Japan). The following antibodies were purchased 
from the indicated sources: a polyclonal anti-human CYP2D6 antibody (Nosan 
Corporation, Kanagawa, Japan); a polyclonal anti-calnexin antibody (Enzo Life 
Sciences, Farmingdale, NY, USA); and a horseradish peroxidase (HRP)-conjugated goat 
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anti-rabbit IgG (Santa Cruz Biotechnology, Santa Cruz, CA, USA). All other chemicals 
were of the highest available commercial grade or analytical grade. 
 
2.2. Expression of CYP2D6 variants in 293FT cells 
Wild-type CYP2D6 and CYP2D6 variants were generated using methods 
described in a previous report [17]. cDNAs were subcloned into the mammalian 
expression vector pcDNA3.4 (Thermo Fisher Scientific, Waltham, MA, USA). 293FT 
cells, purchased from Thermo Fisher Scientific, were cultured in Dulbecco’s modified 
Eagle’s medium (Nacalai Tesque, Kyoto, Japan) containing 10% fetal bovine serum at 
37 ºC, 5% CO2. Cells were transfected with a plasmid (5.0 μg) containing CYP2D6 
cDNA using the TransFectin™ lipid reagent (Bio-Rad Laboratories, Hercules, CA, 
USA) according to the manufacturer’s instructions. After incubation for 24 h at 37 °C, 
the 293FT cells were scraped from the plate, and microsomal fractions were prepared as 
previously described [17]. Protein concentrations were determined using a 
bicinchoninic acid protein assay kit (Thermo Fisher Scientific). 
 
2.3. Western blot analysis 
Western blotting was performed according to standard procedures by 10% sodium 
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dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), with 0.3 μg of 
microsomal protein loaded per lane. CYP2D6 was detected using the polyclonal anti-
human CYP2D6 antibody and HRP-conjugated goat anti-rabbit IgG. Calnexin was 
detected using the polyclonal anti-calnexin antibody and HRP-conjugated goat anti-
rabbit IgG. The immunoblots were visualized using the SuperSignal™ West Dura 
extended duration substrate (Thermo Fisher Scientific). Chemiluminescence was 
quantified using a ChemiDoc™ XRS+ system with the Image Lab software (Bio-Rad 
Laboratories). 
 
2.4. Determination of microsomal P450 content 
The concentrations of CYP2D6 variant holoenzymes were spectrophotometrically 
measured according to previously reported methods [19,20], with several modifications. 
A microsomal fraction (approximately 0.5 mg of microsomal protein) was diluted to a 
final volume of 200 μL using 100 mM potassium phosphate buffer (pH 7.4) containing 
1.0 mM ethylenediaminetetraacetic acid, 20% glycerol (v/v), 0.5% sodium cholate 
(w/v), and 0.4% Triton™ N-101 (w/v). Protein samples (100 μL) were added to the 
sample and reference cuvettes. The cuvettes (sub-micro cells, 16.50-Q-10/Z20) were 
purchased from Starna Scientific, Ltd. (London, UK). A baseline between 400 and 500 
10 
nm was recorded using a Cary 300 UV-Vis spectrophotometer (Agilent Technologies, 
Santa Clara, CA, USA). Carbon monoxide (CO) gas was bubbled through the mixture 
in the sample cuvette at a flow rate of one bubble per second for 20 s. Samples were 
reduced in the presence of approximately 0.2 mg of sodium hydrosulfite. Absorbance 
spectra were then recorded between 400 and 500 nm in both cuvettes using the 
spectrophotometer. CO-difference spectra were recorded in triplicate per CYP2D6 
variant. Data analysis was conducted using Jasco Spectra Manager™ (JASCO 
Corporation, Sendai, Japan). The CYP concentration was calculated using the maximum 
absorbance of three recordings normalized to the baseline spectrum because the baseline 
absorbance varied between 400 and 500 nm. 
 
2.5. Primaquine 5-hydroxylation assay 
The incubation mixture contained primaquine (0.5, 1.0, 2.5, 5.0, 10, 25, 50, 100, 
or 250 μM), 3.3 mM G-6-P, 1.3 mM NADP+, 0.4 U/mL G-6-PDH, 3.3 mM MgCl2, and 
100 mM potassium phosphate buffer (pH 7.4) in a final volume of 100 μL. Following 
preincubation at 37 ºC for 3 min, reactions were initiated by the addition of the 
microsomal fraction (30 μg of protein). After incubation at 37 ºC for 30 min, the 
reactions were terminated by the addition of 100 μL of acetonitrile containing 10 nM 
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mefloquine as an internal standard. The determination of primaquine 5-hydroxylation in 
30 μg of microsomal protein fractions (containing wild-type CYP2D6 or CYP2D6 
variants) showed that 5,6-orthoquinone formation was linear for up to 30 min of 
incubation. Moreover, with a 30-min incubation, 5,6-orthoquinone formation was linear 
in the presence of 0–30 μg of microsomal protein (data not shown). 
After incubation and protein removal by centrifugation (12,000 × g for 10 min), 5 
µL of the supernatant was injected into a liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) system. The NANOSPACE SI-2 LC system, comprised of 
an LC pump, autosampler, oven, and on-line degasser (Shiseido, Tokyo, Japan), was 
used. Separation was performed on an analytical column (XBridge C18; 2.1 mm i.d. × 
100 mm, 3.5-μm particle size; Waters) maintained at 40 °C. Mobile phases were 
prepared by using water containing 0.1% formic acid as eluent A and acetonitrile 
containing 0.1% formic acid as eluent B. The flow rate was 300 μL/min, and the 
gradient program was as follows: initial elution with 100% A, followed by a linear 
gradient to 100% B from 2 to 10 min, 100% B for 2 min, and then immediately returned 
to initial conditions and maintained for 3 min until the end of the run.  
The MS system used in this study was a TSQ Quantiva™ (Thermo Fisher 
Scientific) triple quadrupole mass spectrometer equipped with a heated electrospray 
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ionization (HESI) source. Quantification analyses were performed in a selected reaction 
monitoring mode, in which transitions of the precursor ion to the product ion were 
monitored: m/z 260.2→243.1 for primaquine (collision energy, 15 V), m/z 
260.1→147.1 for the 5,6-orthoquinone form (collision energy, 34 V), and m/z 
379.2→361.1 for mefloquine (collision energy, 26 V). The optimized parameters for 
MS were as follows: positive HESI spray voltage, 3.5 kV; heated capillary temperature, 
300 °C; sheath gas pressure, 40 Arb; auxiliary gas setting, 15 Arb; and heated vaporizer 
temperature, 450 °C. Both the sheath and auxiliary gas was nitrogen. The collision gas 
was argon at a pressure of 1.5 mTorr. The LC-MS/MS system was controlled using the 
Xcalibur™ software (Thermo Fisher Scientific), which was also used for data analysis. 
The retention times of primaquine, 5,6-orthoquinone, and mefloquine were 6.2, 5.3, and 
7.2 min, respectively. The linearity of the quantification of the 5,6-orthoquinone form 
was validated using a crude metabolite synthesized by the method described by 
Bowman et al. [21]. The compound concentrations of all samples were within the 
linearity range. The enzymatic activity was normalized to the corresponding CYP2D6 
holoenzyme level. 
 
2.6. Three-dimensional structural modeling of CYP2D6 
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Three-dimensional structural modeling of CYP2D6 was based on the CYP2D6 
X-ray structure reported by Rowland et al. (Protein Data Bank ID: 2F9Q) [22]. 
Primaquine was docked with the CYP2D6 X-ray structure according to the CDOCKER 
protocol of Discovery Studio 2.5 (BIOVIA, San Diego, CA, USA). Docking iterations 
were conducted taking into consideration that the binding orientation and binding 
energies of the space volume were 12 and that the heme iron was Fe3+. 
 
2.7. Data analysis 
Kinetic data, including the Michaelis constant (Km), maximum velocity (Vmax), 
and intrinsic clearance (CLint = Vmax/Km), were analyzed using the Enzyme Kinetics 
Module of SigmaPlot 12.5 (Systat Software, Inc., Chicago, IL, USA), a curve-fitting 
program based on nonlinear regression analysis. All values are expressed as the mean ± 
standard deviation (SD) of catalytic assays performed in triplicate. Statistical analyses 
of kinetic parameters were performed through analysis of variance, followed by 
Dunnett’s T3 or Kruskal–Wallis post-hoc tests (IBM SPSS Statistics Ver. 22; IBM, 
Armonk, NY, USA). Differences with P < 0.05 were defined as statistically significant. 
 
3. Results 
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CYP2D6 variant proteins expressed in 293FT cells were confirmed by western 
blotting with a polyclonal CYP2D6 antibody that recognized all CYP2D6 variants (Fig. 
2). Calnexin, used as an endoplasmic reticulum resident protein, exhibited constant 
expression levels in microsomes of transfected cells. The CYP2D6 protein was not 
detected in 293FT cells transfected with the empty vector.  
CYP2D6 protein levels were estimated from the CO-difference spectra, and a 
peak at 450 nm was observed for CYP2D6.1 and 27 variants (i.e., 
CYP2D6.2, .9, .14B, .17, .18, .22–.24, .26, .27, .29, .31–.35, .39, .43, .45, .46, .48, .51, .
53, .61, .63, .70, and .71). These results indicate the expression of functional CYP 
enzymes and CYP2D6 variants (Fig. 3). The other 22 CYP2D6 variants (i.e., 
CYP2D6.7, .10, .12, .14A, .25, .28, .30, .36, .37, .40, .47, .49, .50, .52, .54, .55, .57, .62, 
.64, .65, .72, and .75) showed no peak at 450 nm. 
The Michaelis–Menten kinetics for primaquine 5-hydroxylation were measured 
for the 50 CYP2D6 variant proteins. As shown in Table 1, the Michaelis–Menten 
kinetics for primaquine 5-hydroxylation could be determined for 17 CYP2D6 variants: 
CYP2D6.1, .2, .9, .14B, .17, .18, .22–.24, .26, .27, .33, .35, .39, .48, .53, and .70. 
Among them, six variants (i.e., CYP2D6.17, .18, .35, .39, .53, and .70) had significantly 
lower CLint values than that of CYP2D6.1, while the CLint values for CYP2D6.22 
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and .48 were significantly higher. Among the 50 CYP2D6 variants tested, kinetic 
parameters of 33 variants (i.e., 
CYP2D6.7, .10, .12, .14A, .25, .28–.32, .34, .36, .37, .40, .43, .45–.47, .49–.52, .54, .55, 
.57, .61–.65, .71, .72, and .75) could not be determined because the primaquine 5-
hydroxylation activity was not detected.  
Three-dimensional structural modeling was applied to analyze the molecular interactions of 
CYP2D6 variants and primaquine. The V119M substitution in CYP2D6.70 was found forming 
hydrophobic and sulfur-π interactions and changing the heme-binding interactions (Fig. 4). A 
conformational change in CYP2D6.39 harboring the S486T mutation affects substrate recognition 
(Fig. 5). The F120I substitution in CYP2D6.53 lacks the interactions with primaquine, altering 
substrate binding and orientation (Fig. 6). The A90V substitution in CYP2D6.48 modifies the 
interactions with the amino acid residues adjacent to the mutated residue (Fig. 7). 
 
4. Discussion 
CYP2D6 is the key enzyme responsible for the antimalarial activity of 
primaquine, due to its involvement in the generation of active metabolites [9,13,14]. In 
this study, we determined the primaquine metabolic activities of 50 CYP2D6 variant 
alleles using variant proteins overexpressed in 293FT cells. Among the 50 CYP2D6 
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variants studied, kinetic parameters for primaquine 5-hydroxylation were determined for 
the wild type and 16 CYP2D6 variants. In contrast, kinetic parameters of 33 CYP2D6 
variants could not be determined since the amount of the metabolite produced was at or 
below the assay detection limit at lower substrate concentrations. 
Among the 33 inactive variants, 22 variants (i.e., 
CYP2D6.7, .10, .12, .14A, .25, .28, .30, .36, .37, .40, .47, .49, .50, .52, .54, .55, .57, .62, 
.64, .65, .72, and .75) showed no peak at 450 nm after CO treatment, reflecting the 
failed heme incorporation. The majority of no-activity variants harbored amino acid 
substitutions located at the N-terminus of the CYP2D6 enzyme. 
CYP2D6.10, .14A, .36, .37, .47, .49, .52, .54, .57, .64, .65, and .72 harbor the P34S 
substitution located in a highly conserved, proline-rich region [23]. This region 
functions as the hinge between the endoplasmic reticulum membrane anchor and the 
heme-binding portion of the enzyme [24,25]. Mutations of this residue result in an 
unstable protein, and consequently the absorption maximum at 450 nm after CO 
treatment could not be detected among the variants harboring this amino acid 
substitution. The primaquine 5-hydroxylation values for CYP2D6.36, .57, .61, and .63 
were below the assay detection limit; these variants contain a CYP2D7 exon 9 
conversion that includes seven amino acid changes (P469A, T470A, H478S, G479A, 
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F481V, A482S, and S486T). Gaedigk et al. reported that CYP2D6*36 was associated 
with a PM phenotype in vivo, using dextromethorphan as a substrate [15]. We have also 
previously reported that CYP2D6.36 showed no activity in vitro, with bufuralol and N-
desmethyltamoxifen as substrates [17]. The amino acids introduced into exon 9, which 
harbors the substrate recognition site (SRS)-6, may result in the expression of an 
unstable CYP2D6 protein, as well as in altered affinity between the CYP2D6 protein 
and primaquine, leading to a loss of CYP2D6 activity. 
Among the 17 variants with measurable kinetic parameters, CYP2D6.17 and .70 
showed significantly reduced activity, to approximately 50% of the activity observed for 
CYP2D6.1. The CYP2D6*17 allele results in T107I, R296C, and S486T substitutions 
and is commonly found in the African region, which is characterized by the highest 
malaria mortality rate [26,27]. The absorption maximum of CYP2D6.17 at 450 nm after 
CO treatment was 80% lower than that of CYP2D6.1. Yu et al. have also reported that 
the level of the CYP2D6.17 protein expressed in insect cells, measured by the 
difference in CO-reduced spectra, was 50% lower than that of CYP2D6.1 [28]. T107, 
R296, and S486 are located in SRS-1, 4, and 6, respectively [23]. These mutations may 
affect the enzyme activity by altering enzyme stability, as well as primaquine and heme 
affinity. CYP2D6.70 possesses V119M, V136I, V338M, and S486T substitutions. We 
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have previously reported that the CLint value of CYP2D6.70 was 68% lower than that of 
CYP2D6.1 when using N-desmethyltamoxifen as a substrate [17]. V119, located in the 
CYP2D6 SRS-1 region, forms a hydrophobic interaction with R132 (Fig. 4) [23]. The 
V119M substitution creates hydrophobic and sulfur-π interactions between M119 and 
the heme, while M119 forms a hydrophobic interaction with L444. The heme-binding 
region containing L444 is conserved in the CYP family and conformational changes 
near the heme moiety affect protein function [23]. Consequently, these interactions 
adjacent to the active site cavity lead to reduced activity. 
CYP2D6.18, .35, .39, and .53 showed considerably decreased activities for 
primaquine 5-hydroxylation, less than 30% of that of the wild-type CYP2D6.1. The 
CYP2D6*18 allele contains a repetitive 9-base insertion in exon 9, causing an insertion 
of VPT after amino acid residue 470. This inserted VPT is positioned in the β3 strand 
near SRS-6, and thus this mutation may be involved in determining the conformation of 
SRS-6 [23]. CYP2D6.35, which contains V11M, R296C, and S486T substitutions, 
showed 73% less activity than did CYP2D6.1. We have previously reported that 
CYP2D6.35 showed no activity toward N-desmethyltamoxifen [17]. The V11 residue is 
located in the membrane-anchoring region [23]. The CLint value for CYP2D6.2 (R296C 
and S486T) with respect to primaquine 5-hydroxylation was almost the same as that of 
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CYP2D6.1. The V11M substitution may cause an anchoring instability between the 
enzyme and the endoplasmic reticulum membrane [24]. The activity of CYP2D6.39, 
containing an S486T substitution, was 6% of the control activity (CYP2D6.1). We have 
previously reported that CYP2D6.39 exhibited a 30% decrease in its CLint value 
compared with that of CYP2D6.1 for N-desmethyltamoxifen metabolism, whereas 
CYP2D6.39 showed almost the same activity as that of wild-type CYP2D6.1, using 
bufuralol as a substrate [17,29]. Tsuzuki et al. have that the CYP2D6.39 activity for 
debrisoquine metabolism was 60% as compared with that of the control [30]. S486, positioned in 
the SRS-6 β4 strand, forms hydrogen bonds with G479 and V480 (Fig. 5). The S486T 
substitution produces hydrogen bond interactions with P487, which causes a 
deterioration in flexibility of the β4 strand. These interactions change the active site 
cavity, affecting substrate specificity. 
CYP2D6.53 exhibited a seven-fold increase in the Km value, resulting in an 88% 
decrease in its CLint value compared with that of wild-type CYP2D6.1. We have 
previously reported that CYP2D6.53 exhibited a 28-fold increase in the CLint value for 
N-desmethyltamoxifen metabolism compared with that of CYP2D6.1 [17]. In addition, 
we have reported that CYP2D6.53 showed a four-fold increase in its CLint value when 
using bufuralol as a substrate [29]. These results, obtained using recombinant enzymes, 
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were derived from lower Km values than that of CYP2D6.1. CYP2D6.53 contains F120I 
and A122S substitutions in SRS-1 [23]. Flanagan et al. have reported that the F120 
residue plays an important role in substrate binding and orientation [31]. Keizers et al. 
have also reported that the F120 residue affects the affinity, turnover, and orientation of 
substrates [32]. The F120 residue forms two π–π interactions with the quinoline core of 
primaquine and a carbon–hydrogen bond interaction with the heme, fixing primaquine 
within the substrate pocket (Fig. 6). The F120I substitution eliminates the two π–π 
interactions and forms a π–alkyl interaction with the heme. Masuda et al. have 
suggested that the phenyl ring of the F120 residue affects the positioning of the aromatic 
ring of the substrate in the active site of CYP2D6 and that the substrate is positioned in 
proximity to an activated oxygen molecule coordinated to a heme iron [33]. The 
decrease in the CLint value of CYP2D6.53 appears to stem from an alteration in 
substrate binding, and individuals with CYP2D6*53 may present with the PM 
phenotype for primaquine. 
CYP2D6.22 and .48 showed a 1.9- and 1.6-fold increase in CLint values, 
respectively, compared with that of CYP2D6.1. CYP2D6.22 has a substitution in 
residue S28, located in the transmembrane domain near the proline-rich region [23]. The 
CO-binding spectra indicated that the absorbance at 450 nm decreased and that at 420 
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nm increased compared with those of CYP2D6.1. The S28C substitution is believed to 
affect the correct folding or expression of the holoenzyme, thereby increasing the Vmax 
value. CYP2D6.48, which contains the A90V substitution, showed a 1.6-fold increase in 
CLint due to a decrease in Km and Vmax values. We have previously reported that 
CYP2D6.48 exhibited a 30% decrease in the CLint value compared with that of 
CYP2D6.1, using N-desmethyltamoxifen as a substrate [17]. In addition, we have 
reported that CYP2D6.48 showed a 1.6-fold increase in its CLint value compared with 
that of wild-type CYP2D6.1, when using bufuralol [29]. The A90 residue, positioned in 
the αB helix, forms hydrophobic interactions with L81, G95, and V384 (Fig. 7). The 
A90V substitution causes the disappearance of the G95 interaction and forms a 
hydrophobic interaction with L395 instead. These amino acid residues are located in the 
β1 strand. Wade et al. have reported that the substrate passes between the tip of the B-C 
loop and the β1 sheet [34]. This channel appears to be important for substrate 
specificity, because SRS-1 is located between the B helix and C helix. The 
conformational changes caused by the A90V substitution might lead to increased 
enzymatic activity for primaquine. 
There are limitations in phenotype prediction using in vitro data. Differences in 
CO-reduced spectra were used to determine P450 concentrations, and the data suggested 
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that some CYP2D6 variant proteins decreased the heme incorporation into apoprotein. 
However, the expression levels and protein stabilities may be different in vivo and in 
vitro. Stability determinations of the variant proteins using denaturation experiments at 
various temperatures would be helpful in uncovering structure–function relationships. 
Moreover, further studies will be needed to define the importance of CYP2D6 allelic 
variants in clinical settings.  
In conclusion, the wild type and 49 CYP2D6 variants were expressed in 293FT 
cells, and their primaquine metabolic activities were characterized in vitro. CYP2D6 is 
an important P450 isoform involved in the activation of primaquine; hence, alterations 
in the primaquine 5-hydroxylation activity, caused by CYP2D6 allelic variants, were 
determined for the first time. These findings provide further insight into primaquine 
allele-specific activity of CYP2D6 and may be clinically beneficial for malaria 
eradication efforts. 
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Figure Legends 
 
Fig. 1. Primaquine metabolic pathways mediated by CYP2D6 and MAO-A. The 
primaquine aldehyde and subsequent carboxy metabolite are formed through the MAO-
A pathway. Primaquine hydroxylation at position 5, mediated by CYP2D6, produces 
unstable intermediates. 5-Hydroxyprimaquine is capable of redox cycling to the quinone 
imine form. These species are inherently unstable and react with water to form the 
stable 5,6-orthoquinone form. CYP2D6, cytochrome P450 2D6; MAO-A, monoamine 
oxidase A. 
 
Fig. 2. Representative western blots showing immunoreactive CYP2D6 proteins (upper 
panel) and the calnexin loading control (lower panel). Western blotting was performed 
according to standard procedures using 10% SDS-PAGE. Microsomal fractions 
containing CYP2D6 variant proteins were loaded in each lane. CYP2D6 variants and 
calnexin were detected using respective polyclonal antibodies. The lane numbers 
correspond to each CYP2D6 variant. CYP2D6, cytochrome P450 2D6. 
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Fig. 3. The ferrous-CO versus ferrous difference spectrum was used to quantify the 
preparation of human CYP2D6 variant proteins from 293FT cells. The numbers 
correspond to each CYP2D6 variant. CYP2D6, cytochrome P450 2D6. 
 
Fig. 4. Diagram showing a fragment of the crystal structures of CYP2D6.1 (left panel) 
and CYP2D6.70 (right panel). Primaquine is shown in blue, and the heme is shown in 
red. CYP, cytochrome P450. 
 
Fig. 5. Diagram showing a fragment of the crystal structures of CYP2D6.1 (left image) 
and CYP2D6.39 (right image). Primaquine is shown in blue, and the heme is shown in 
red. CYP, cytochrome P450. 
 
Fig. 6. Diagram showing a fragment of the crystal structures of CYP2D6.1 (left image) 
and CYP2D6.53 (right image). Primaquine is shown in blue, and the heme is shown in 
red. CYP, cytochrome P450. 
 
Fig. 7. Diagram showing a fragment of the crystal structures of CYP2D6.1 (left image) 
and CYP2D6.48 (right image). The heme is shown in red. CYP, cytochrome P450. 
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Table 1 
Primaquine 5-hydroxylation kinetic parameters of the wild type and CYP2D6 variants expressed in 293FT cells. 
Variants Nucleotide changes Amino acid changes Km (μM) 
Vmax 
(Area ratio/min/pmol P450) 
CLint (Vmax/Km) % of wild type 
CYP2D6.1   15.7±2.0 1.39±0.07 0.0761±0.0066  
CYP2D6.2 2850C>T; 4180G>C R296C; S486T 32.4±3.7 2.32±0.11** 0.0719±0.0047 82% 
CYP2D6.9 2615_2617delAAG K281del 20.2±1.0 1.06±0.03 0.0523±0.020 60% 
CYP2D6.14B 100C>T; 4180G>C P34S; S486T 69.9±9.7* 3.60±0.31* 0.0517±0.0026 59% 
CYP2D6.17 1023C>T; 2850C>G; 4180G>C T107I; R296C; S486T 83.0±25.6*** 2.95±0.40* 0.0367±0.0056* 42% 
CYP2D6.18 4125_4133dupGTGCCCACT 468_470dupVPT 260±52*** 1.66±0.25 0.00645±0.00050* 7.4% 
CYP2D6.22 82C>T R28C 19.6±0.2 3.29±0.15** 0.168±0.006*** 192% 
CYP2D6.23 957C>T A85V 45.7±9.1* 3.20±0.22* 0.0710±0.0085 81% 
33 
CYP2D6.24 2853A>C I297L 17.0±5.1 1.31±0.11 0.0797±0.0152 91% 
CYP2D6.26 3277T>C I369T 23.5±2.9 2.61±0.14* 0.112±0.007 127% 
CYP2D6.27 3853G>A E410K 29.5±3.6 1.91±0.14 0.0650±0.0034 74% 
CYP2D6.33 2483G>T A237S 12.5±1.3 0.807±0.023* 0.0647±0.0049 74% 
CYP2D6.35 31G>A; 2850C>G; 4180G>C V11M; R296C; S486T 16.8±2.4 0.401±0.024** 0.0240±0.0022* 27% 
CYP2D6.39 4180G>C S486T 351±46*** 1.94±0.25 0.00555±0.00032* 6.3% 
CYP2D6.48 972C>T A90V 6.05±0.53 0.856±0.017* 0.142±0.0098* 162% 
CYP2D6.53 1611T>A; 1617G>T F120I; A122S 104±20*** 1.09±0.19 0.0105±0.0005* 12% 
CYP2D6.70 1608G>A; 1659G>A; 1611G>C; 
3183G>A; 4180G>C 
V119M; V136I; V338M; 
S486T 
16.5±1.6 0.819±0.027* 0.0500±0.0032* 57% 
The data represent the mean ± SD of three independently performed catalytic assays. 
*P < 0.05, **P < 0.01, and ***P < 0.005 compared with CYP2D6.1.  
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The kinetic parameters for primaquine 5-hydroxylation of CYP2D6.7, .10, .12, .14A, .25, .28–.32, .34, .36, .37, .40, .43, .45–.47, .49–.52, .54, .55, .57, .61–.65, .71, .72, 
and .75 could not be determined because the enzymatic activity of CYP2D6 was not detected at the highest substrate concentration tested (250 μM primaquine). 
 
